A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2001
11/08/2001	WO2001083524A2 Rna metabolism proteins
11/08/2001	WO2001083513A2 Antisense modulation of inhibitor of dna binding-1 expression
11/08/2001	WO2001083512A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	WO2001083510A1 29 human secreted proteins
11/08/2001	WO2001083503A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
11/08/2001	WO2001083489A1 THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
11/08/2001	WO2001083486A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	WO2001083450A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001	WO2001083445A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/08/2001	WO2001083434A2 P-(sulfonyl)-aryl and heteroaryls amines
11/08/2001	WO2001083427A1 PPARη MODULATORS
11/08/2001	WO2001083385A2 Devices and method for production of traceable immunizing drinking water, other liquids and gas
11/08/2001	WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001	WO2001082960A1 Inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions
11/08/2001	WO2001082958A2 Methods of producing membrane vesicles
11/08/2001	WO2001082957A1 Snthetic vaccine for tick control
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001082948A2 Uses of tgap7 for the modulation of leucocyte activation
11/08/2001	WO2001082940A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001	WO2001082911A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
11/08/2001	WO2001082888A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001	WO2001082720A1 Pet food composition for reducing inflammatory response in cats
11/08/2001	WO2001082719A1 Process for enhancing immune response in canines using a dietary composition including garlic
11/08/2001	WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001	WO2001049657A8 2-`3-amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors
11/08/2001	WO2001044242A9 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001036630A3 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
11/08/2001	WO2001034617A3 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
11/08/2001	WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001	WO2001032128A3 Human chemokine beta-13
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001026680A3 Activation of antigen-specific t cells by virus/antigen-treated dendritic cells
11/08/2001	WO2001018035A3 Muc-1 derived peptides
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	WO2001002551A3 Virus like particles, preparation and use in screening and functional genomics
11/08/2001	WO2000069897A3 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/08/2001	US20010039669 Polynucleotide comprising caprine arthritis encephalitis virus (CAEV) viral genome renders nonpathogenic to a primate a resulting retroviral particle produced via gene expression, generating immune response against HIV-1
11/08/2001	US20010039479 Three-dimensional model of a Fc region of an IgE antibody and uses thereof
11/08/2001	US20010039392 Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
11/08/2001	US20010039289 Antagonists; especially sodium salts
11/08/2001	US20010039282 Desloratadine as non-sedating antihistamine, decongestant
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039273 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
11/08/2001	US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001	US20010038843 Immunogenic polypeptide comprising a self Immunoglobin E (IgE) portion and a non-self IgE portion, to induce an anti-self IgE response in a mammal; treating diseases such as allergies
11/08/2001	US20010038840 Method for the treatment of fibrosis
11/08/2001	DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001	CA2750984A1 Porphyromonas gingivalis recombinant proteins and truncations
11/08/2001	CA2418748A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2408105A1 Novel proteases
11/08/2001	CA2408011A1 Splice-region antisense composition and method
11/08/2001	CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	CA2407956A1 Modified peptides as therapeutic agents
11/08/2001	CA2407942A1 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
11/08/2001	CA2407799A1 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001	CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
11/08/2001	CA2407746A1 Proteases
11/08/2001	CA2407709A1 Regulated antigen delivery system (rads) involving bacteria
11/08/2001	CA2407700A1 Compositions and methods for inducing activation of dendritic cells
11/08/2001	CA2407604A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001	CA2407597A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	CA2407587A1 Ppar.gamma. modulators
11/08/2001	CA2407435A1 Rna metabolism proteins
11/08/2001	CA2407399A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/08/2001	CA2407334A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001	CA2407314A1 Process for enhancing immune response in canines using a dietary composition including garlic
11/08/2001	CA2407294A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001	CA2407225A1 Methods of producing membrane vesicles
11/08/2001	CA2406743A1 Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
11/08/2001	CA2405832A1 P-(sulfonyl)aryl and heteroaryls
11/08/2001	CA2403901A1 29 human secreted proteins
11/08/2001	CA2377629A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/07/2001	EP1152243A1 DIagnosis of Sjögren's syndrome, systemic lupus erythematosis, and scleroderma via detection of anti-retroviral antibodies
11/07/2001	EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
11/07/2001	EP1152007A1 Ether type lipid a1-carboxylic acid analogues
11/07/2001	EP1152002A1 Pyrrole derivatives and cell death inhibitors
11/07/2001	EP1151113A2 Human peptidases
11/07/2001	EP1151109A1 Fucosyl transferase gene
11/07/2001	EP1151107A1 Basb059 polypeptides from neisseria meningitidis
11/07/2001	EP1151101A1 Prostacyclin-stimulating factor-2
11/07/2001	EP1151067A1 Process of converting rendered triglyceride oil from marine sources into bland, stable oil
11/07/2001	EP1151011A1 Anti-ccr1 antibodies and methods of use therefor
11/07/2001	EP1151010A2 Human polyclonal antibodies from transgenic nonhuman animals
11/07/2001	EP1151005A1 Peptide variants of the tumour marker muc1 and the use thereof
11/07/2001	EP1151001A2 Method for altering undesirable immune responses to polypeptides
11/07/2001	EP1150997A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
11/07/2001	EP1150995A1 A synthetic peptide disturbing intracellular signaling
11/07/2001	EP1150994A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
11/07/2001	EP1150991A2 Compositions for treating inflammatory response
11/07/2001	EP1150970A1 (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
11/07/2001	EP1150960A1 Polymorphic crystalline forms of celecoxib
11/07/2001	EP1150959A1 Solid-state form of celecoxib having enhanced bioavailability
11/07/2001	EP1150954A1 Anti-imflammatory indole derivatives
11/07/2001	EP1150953A1 Indole derivatives and their use as mcp-1 receptor antagonists

1 ... 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 ... 1172